Advertisement

Topics

Latest "Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years" News Stories

12:48 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years" found in our extensive news archives from over 250 global news sources.

More Information about Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years for you to read. Along with our medical data and news we also list Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years Clinical Trials, which are updated daily. BioPortfolio also has a large database of Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years Companies for you to search.

Showing "Growth Hormone Treatment Prevention Short Stature Young Girls" News Articles 1–25 of 27,000+

Tuesday 26th March 2019

The Proposed Noorda College of Osteopathic Medicine Board of Trustees Holds Inaugural Meeting

Inaugural Trustees and officers instated The Board of Trustees for the proposed Noorda College of Osteopathic Medicine met for the first time Monday and instated Trustee members and approved bylaws and policies. Francis Gibson, MSW, MBA, Utah House Representative and House Majority Leader, and CEO of Orem Community Hospital was appointed Chair. ...


Perspectum Diagnostics Named Fastest Growing UK-based Life Science Company

Perspectum has been named by Beauhurst as the fastest growing Life Science Company in the UK. Beauhurst, specialists in assessing start-ups and fast-growing British companies, released the findings earlier this month. Perspectum’s turnover growth was measured against 23,000 other companies, with results setting it in first place. This rapid grow...

Promedior Receives Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis

LEXINGTON, Mass., March 26, 2019 /PRNewswire/ — Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that PRM-151, a novel investigational anti-fibrotic immunomodulator, has been granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for Idiopathic Pulmonary Fibrosis (IPF).&...


Virginia Tech Launches Clinical Trial for Rehabilitating Infant Stroke Victims

Senior therapist Mary Rebekah Trucks in a rehabilitation session with a young patient Virginia Tech, today announced the launch of the nation’s first multicenter pediatric stroke recovery trial for researchers and clinicians from 12 sites across the United States will evaluate an innovative therapeutic approach to help 8-month-old to 24-month-old infants. Named The clinical trial ... Read Mo...

Avanir Reports Phase 3 Data of Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer’s Dementia

ALISO VIEJO, Calif., March 25, 2019 /PRNewswire/ — Avanir Pharmaceuticals, Inc. announced today the results from the first study of the company’s phase 3 clinical development program investigating the efficacy, safety and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of moderate-to-severe agitation in patients with Alzheimer&...

HER2+ Breast Cancer Paradigm Slated to Expand With Novel Therapies

Melody A. Cobleigh, MD, sheds light on novel treatment approaches for patients with HER2-positive breast cancer that are under investigation as well as strategies that have already been incorporated into practice.

Progress Continues in HR+/HER2- Breast Cancer Paradigm

Kristin J. Richardson, MD, highlights advances made with CDK4/6 inhibitors in the treatment of patients with hormone receptor-positive metastatic breast cancer and forecasts where treatment is headed in this space.

Ascendis Pharma’s Phase 3 Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon hGH to a Daily Growth Hormone

COPENHAGEN, Denmark, March 24, 2019 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address unmet medical needs, today announced top-line results from its pivotal phase 3 heiGHt Trial were presented at the Endocrine Society’s annual meeting, ENDO 2019, in New Orleans. Trial results demonstrated that R...

New Ventures BC and BioTalent Canada Announce Partnership to Maximize BC Biotech’s Access to Top Talent

New Ventures BC and BioTalent Canada today announced a new partnership to assist BC biotech companies to access funding to hire post-secondary students for business and tech roles to help drive their objectives forward. The Innovate BC Innovator Skills Initiative (ISI) grant program was launched by New Ventures BC in June 2018 and is now accepting...

Elite Hearing Network Welcomes New Senior Vice President

Elite Hearing Network, the largest network of independent hearing care providers in the United States, has named Gray Fleming to the role of Senior Vice President. Mr. Fleming joins Elite after a long-standing, successful career at Abbott (formerly St. Jude Medical), where he most recently held the title of Vice President of Cardiac Sales. Am...

Takeda Presents New Data at the Endocrine Society’s 2019 Annual Meeting about the Patient Burden and Long-Term Impact of Chronic Hypoparathyroidism

Impact on patient quality of life quantified including long-term renal and cardiovascular complications Final outcomes of 6 year study into continuous use of rhPTH(1-84) shows improvements in key measurements of mineral homeostasis Takeda Pharmaceutical Company Limited (

Humana Employees Reach Bold Goal, Achieving 20 Percent more Healthy Days

Employees gained 2.3 million Healthy Days over the past few years and set a new goal of 500,000 more by 2022 Employees of Humana Inc. (NYSE: HUM) have reached their Bold Goal of achieving 20% more Healthy Days, gaining 2.3 million more Healthy Days – or roughly an extra week of better days per year for each associate – compared to their...

Nexstim Oyj: EUR 5.2 million rights issue Of Nexstim Oyj

Company announcement, Helsinki, 26 March 2019 klo 15.20 Nexstim Oyj: EUR 5.2 million rights issue Of Nexstim Oyj NOT TO BE PUBLISHED OR DISTRIBUTED DIRECTLY OR INDIRECTLY TO THE UNITED STATES OF AMERICA, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTHERN AFRICA OR TO ANY OTHER COUNTRY WHERE THE DISTRIBUTION OR PUBLICATION IS ILLEGAL.Nexstim Plc (NXTMH:HEX, N...

Prostate Cancer “Spews” Tumor-Promoting Protein on Neighbors

Scientists at the University of Bradford and the University of Surrey have shown how prostate cancer cells release a protein that is taken up by surrounding normal and cancer cells, and which may promote tumor growth and help protect the cancer from the body’s immune system. The post Prostate Cancer “Spews” Tumor-Promoting Protein on Neighbors appeared first on GEN - Genetic Engineering and ...

Confirm BioSciences Secures Funding with HCAP Partners to Accelerate Global Expansion

New Investment to Fuel New Product Innovations and Strategic Growth SAN DIEGO (PRWEB) March 26, 2019 Confirm BioSciences, the San Diego, CA-based leader for high-quality diagnostic testing and health & wellness solutions for both the corporate community and individual consumers, today announced it has secured impact financing from HCAP Partners, a California-based private equity firm and reco...

Mississippi Hospital Live on Evident’s Thrive EHR System

Lackey Memorial Hospital Now Has Access to Patient Information with Thrive EHR Across the Hospital and Emergency Department Settings Evident LLC, a wholly owned subsidiary of CPSI (NASDAQ: CPSI) and a leading provider of electronic health record (EHR) systems and services, announced today that Lackey Memorial Hospital is live on the Thrive EHR solution...

Postpartum depression: new drug will be monitored at approved sites

The first drug approved by the US Food and Drug Administration for the treatment for postpartum depression will be administered only to short term inpatients at specially approved sites, as the FDA...

Elekta Unity MR-linac receives medical device license from Health Canada

“We are pleased to have achieved this important milestone toward making Elekta Unity available in Canada and expect that this important new treatment option will become available to The post Elekta Unity MR-linac receives medical device license from Health Canada appeared first on Compelo Medical Devices - Latest industry news and analysis.

STAT Plus: With an experimental NASH treatment, NGM aims to be the next billion-dollar biotech

NGM Biopharmaceuticals wants to be the next billion-dollar biotech on Wall Street, and so it's moving forward with an IPO that offers a springtime referendum on investor sentiment.

Eisai, Biogen move Alzheimer’s treatment into Phase III

Eisai and Biogen's BAN2401 is to be put into Phase III trial for patients with early Alzheimer's disease.

UBCF to hold Pink Bag Event® at Barclays Center, Brooklyn, NY

Breast Health Education & Cancer Prevention Event Open to All HUNTINGTON STATION, N.Y. (PRWEB) March 26, 2019 United Breast Cancer Foundation (UBCF) is proud to announce their partnership with the Barclays Center in Brooklyn, NY. Through this partnership, UBCF will be hosting an Educational Outreach and Pink Bag Event® at the Barclays Center in Brooklyn, NY on Wednesday, April 3rd from 8...

A New Edition of Maternal and Child Health Journal Is Now Available

Maternal and Child Health Journal (vol. 22, no. 12, 2018) is available online by subscription only. Articles include: “Progress Toward Eliminating Mother to Child Transmission of HIV in Kenya: Review of Treatment Guidelines Uptake and Pediatric Transmission Between 2013 and … Read More

Helping Each New Generation of Parents Tackle the Age-Old Challenge of Head Lice—Safely and Effectively

The National Pediculosis Association Continues its Leadership Role with New Educational Resources and the Tools to CombFirst! NEWTON, Mass. (PRWEB) March 26, 2019 No matter how each new generation of parents differs from its predecessors, one fact remains the same—sooner or later, they will be challenged by a lice infestation first identified at school, a childcare center, or camp. What’s cha...

58% of Smokers Wouldn't Quit for 10 Years of Extra Life, According to Vantis Life

1/3 Say Health Warnings Aren’t Good Enough Over half (58%) of American smokers would not give up smoking, even if it meant they could live 10 years longer, according to new research released by Vantis Life. The survey of over 2,000 Americans* investigated respondents’ current habits and how willing they would be to change. Of those ...

Covetrus Announces Appointment of Matthew Leonard as Executive Vice President, President North America and Global Supply Chain Officer

Leonard Brings Significant Expertise in Technology, Procurement and Supply Chain Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, announced today that Matthew Leonard has been named Executive Vice President, President North America and Global Supply Chain Officer effective April 8, 2019. In his role, Leonard will ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks